Skip to main content
The University of Arizona Wordmark Line Logo White
Stories & Features Announcements Calendar Leadership Updates Event Planning Room Scheduling Café Bolo Directories IT Support Classroom Support Planning & Facilities
The University of Arizona Health Sciences | Home
Subscribe
Support
home home

Main navigation

  • Overview Senior Leadership Academic Leadership Executive Leadership Annual Report Mission, Values, History Support
  • Overview College of Health Sciences College of Medicine – Phoenix College of Medicine – Tucson College of Nursing Mel and Enid Zuckerman College of Public Health R. Ken Coit College of Pharmacy
  • Research Administration Research Awards and Grants
  • Clinical
  • Overview Community Engagement Alliance Corporate and Community Relations Health and Humanities Rural Health Community Events Student Engagement and Career Advancement
  • Overview Aegis Consortium All of Us Research Program Arizona Area Health Education Centers Arizona Simulation Technology & Education Center Asthma & Airway Disease Research Center Center for Accelerated Biomedical Innovation Center for Advanced Molecular & Immunological Therapies Center for Biomedical Informatics & Biostatistics Center for Disparities in Diabetes, Obesity & Metabolism Center for Innovation in Brain Science Center for Sleep, Circadian & Neuroscience Research Clinical & Translational Sciences Research Center Comprehensive Center for Pain & Addiction Health Sciences SensorLab One Health University of Arizona Cancer Center
  • All News Stories Videos The Healthy Dose Blog News Releases In The Media Media Resources Office of Communications
  1. Home
  2. Node

Crisis Response - Trauma Informed Care Project

Read more about Crisis Response - Trauma Informed Care Project

Inflammatory Bowel Disease West Case Conference

Read more about Inflammatory Bowel Disease West Case Conference

Prospective Evaluation of Cryoneurolysis of the Pudendal Nerve (PEC)

Read more about Prospective Evaluation of Cryoneurolysis of the Pudendal Nerve (PEC)

Assessment of Long Term Endovascular AAA Intervention using the GORE EXCLUDER Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

Read more about Assessment of Long Term Endovascular AAA Intervention using the GORE EXCLUDER Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

An Open-label Single-Arm Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patien

Read more about An Open-label Single-Arm Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patien

An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension

Read more about An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension

A Two-Arm Randomized, Double-Blind, Placebo- Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination with Atezolizumab in Patients with HPV16-Positive

Read more about A Two-Arm Randomized, Double-Blind, Placebo- Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination with Atezolizumab in Patients with HPV16-Positive

A Research Study to Advance the CF Therapeutics Pipeline for People without Modulators

Read more about A Research Study to Advance the CF Therapeutics Pipeline for People without Modulators

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact

Read more about A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact

A Phase 1b/2a, Double-Blind, Placebo-Controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV)

Read more about A Phase 1b/2a, Double-Blind, Placebo-Controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV)

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • Next › Next page
  • Last » Last page
Subscribe to
The University of Arizona Health Sciences | Home

Health Sciences

  • About
  • Academics
  • Research
  • Centers and Programs
  • Clinical Care
  • Outreach
  • Initiatives

News

  • Stories
  • Healthy Dose Blog
  • News Releases
  • In The Media
  • Media Resources
  • Videos

Internal Resources

  • Stories & Features
  • Announcements
  • Calendar
  • Leadership Updates
  • Honors and Awards
  • Event Planning
  • Room Scheduling
  • Café Bolo
  • El Mirador Project
  • IT Support
  • Classroom Support
  • Planning and Facilities
  • Photo Galleries
  • Directories

Connect

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • X, formerly Twitter

We respectfully acknowledge the University of Arizona is on the land and territories of Indigenous peoples. Today, Arizona is home to 22 federally recognized tribes, with Tucson being home to the O’odham and the Yaqui. The university strives to build sustainable relationships with sovereign Native Nations and Indigenous communities through education offerings, partnerships, and community service.


University Information Security and Privacy

© 2025 The Arizona Board of Regents on behalf of The University of Arizona.